Fouling and cleaning of membrane--a literature review

1　ＩｎｔｒｏｄｕｃｔｉｏｎＤｕｒｉｎｇｔｈｅｐａｓｔｆｅｗｙｅａｒｓ,ｍｅｍｂｒａｎｅｓｅｐａｒａｔｉｏｎｓｈａｖｅｂｅｃｏｍｅｍｏｒｅｗｉｄｅｌｙｕｓｅｄ,ａｎｄｒｅｐｌａｃｅｄｓｏｍｅｏｆｔｈｅｃｏｎｖｅｎｔｉｏｎａｌｃｏｎｃｅｎｔｒａｔｉｏｎｔ?..     

Prenatal diagnosis of congenital head,face, and neck malformations—Is complementary fetal MRI of value?

Objectives

The aim of this study was to evaluate the role of fetal magnetic resonance imaging (MRI) as a complement to ultrasound (US) in the prenatal diagnosis of craniofacial anomalies.

Methods

A historical cohort study including all pregnant women who were referred for fetal MRI because of antenatal diagnosis of craniofacial anomalies on screening US. Prenatal diagnostic US, MRI, and postnatal diagnosis were compared for consistencies and discrepancies.

Results

Forty-five pregnant women with 73 suspected fetal craniofacial anomalies diagnosed by US underwent MRI. In 40 out of 73 anomalies (54.8%), US and MRI findings were in complete agreement with postnatal diagnoses. MRI correctly ruled out the diagnosis of 24 anomalies suspected on US and diagnosed four additional pathologies that were not demonstrated by US. Out of the 85 anomalies (suspected by imaging or confirmed postnatally), confident diagnosis could be made by MRI in 68 anomalies (80%), not diagnosed in 10 (11.8%), and over-diagnosed in seven (8.2%). By US, confident diagnosis could be made in 44 anomalies (51.8%), not diagnosed in 11 (12.9%), and over-diagnosed in 30 (35.3%).

Conclusion

MRI is valuable in the antenatal evaluation of fetal craniofacial anomalies and may be useful as an adjunct to US in the prenatal work-up of craniofacial anomalies.     

Prenatal diagnosis of sex chromosome aneuploidy—What do we tell the prospective parents?

Sex chromosome aneuploidy (SCA) can be detected on prenatal diagnostic testing and cell free DNA screening (cfDNA). High risk cfDNA results should be confirmed with diagnostic testing. This summary article serves as an update for prenatal providers and assimilates data from neurodevelopmental, epidemiologic, and registry studies on the most common SCA. This information can be helpful for counseling after prenatal diagnosis of sex chromosome aneuploidy. Incidence estimates may be influenced by ascertainment bias and this article is not a substitute for interdisciplinary consultation and counseling.     

Algal-bloom control by allelopathy of aquatic macrophytes——A review

Algal-bloom control is an important issue for water environment protection as it induces several negative impacts on the lives of aquatic organisms, aquaculture, landscaping, and human health. The development of an environment-friendly, cost-effective, and convenient alternative for controlling algal bloom has gained much concern. Using the allelopathy of aquatic macrophytes as a novel and safe method for algal-bloom control is a promising alternative. This paper reviews the development and potential application about allelopathy of aquatic plants on algae, including the allelopathic research history, the potential research problems, the research methodology, and the reported aquatic macrophytes and their inhibitory allelochemicals. Potential modes of inhibition action of allelochemicals on algae, possible ways for application, and future development directions of research on algal-bloom control by aquatic macrophytes were also presented.     

Prenatal diagnosis of cleft lip and/or palate: What do we tell prospective parents?

Cleft lip and/or palate (CL/CP) is the most common congenital craniofacial anomaly and parents often ask, “how did this happen?” Patients and families may benefit from access to a multidisciplinary team (MDT) from prenatal diagnosis into early adulthood. Multiple factors can contribute to the development of a cleft. We discuss the epidemiology and risk factors that increase the likelihood of having a newborn with a cleft. The purpose of this article is to review the prenatal investigations involved in the diagnosis and workup of these patients in addition to postpartum treatment, prognostic factors, and counseling families regarding future recurrence risk.